Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days' gestation. by Hsia, Jennifer K et al.
UC Davis
UC Davis Previously Published Works
Title
Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days' 
gestation.
Permalink
https://escholarship.org/uc/item/73s041cf
Journal
Contraception, 100(3)
ISSN
0010-7824
Authors
Hsia, Jennifer K
Lohr, Patricia A
Taylor, Jeanette
et al.
Publication Date
2019-09-01
DOI
10.1016/j.contraception.2019.05.006
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Contraception 100 (2019) 178–181
Contents lists available at ScienceDirect
Contraception
j ourna l homepage: www.e lsev ie r .com/ locate /conOriginal research articleMedical abortion with mifepristone and vaginal misoprostol between 64
and 70 days' gestation☆,☆☆Jennifer K Hsia a,1, Patricia A Lohr b, Jeanette Taylor b, Mitchell D Creinin a,⁎
a Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, USA
b British Pregnancy Advisory Service, Stratford Upon Avon, UK☆ Presented in part as a poster abstract at the 2018
Annual Meeting.
☆☆ Conﬂicts of interest: Dr. Hsia declares no conﬂicts of i
tion. Dr. Lohr and Mrs. Taylor are employees of British P
Creinin receives compensation from Danco for providing
to clinicians who call for expert advice on mifepristone.
⁎ Corresponding author. Tel.:+1 916 734 6670.
E-mail address:mdcreinin@ucdavis.edu (M.D. Creinin
1 Dr. Hsia's current afﬁliation is Department of Obstet
Medical Foundation, Mountain View, CA, USA.
https://doi.org/10.1016/j.contraception.2019.05.006
0010-7824/© 2019 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 19 February 2019
Received in revised form 2 May 2019
Accepted 8 May 2019Objective: To evaluate outcomeswithmifepristone 200mg orally followed 24–48 h later bymisoprostol 800mcg
vaginally for medical abortion at 64–70 days of gestation.
Study design:We reviewed electronic databases and medical records for medical abortion cases at 64–70 days'
gestation at British Pregnancy Advisory Service clinics in England and Wales from May 2015 through October
2016. Women selected in-ofﬁce follow-up or self-evaluation of abortion outcome using a checklist along with
low-sensitivity urine pregnancy testing. We excluded cases in which we could not locate records and when
women did not proceed with medical abortion, did not use misoprostol following mifepristone if abortion had
not occurred and did not attend a scheduled follow-up assessment. We analyzed demographic characteristics,
treatment outcomes and signiﬁcant adverse events.We deﬁned treatment success as complete abortionwithout
surgical evacuation and without continuing pregnancy.
Results: Of 2743 cases identiﬁed, we could not locate 40 charts and excluded 30 cases, leaving a ﬁnal sample of
2673. Overall, 2538 (94.9%, 95% CI 94.1–95.8) women had a successful medical abortion. Reasons for failure in-
cluded continuing pregnancy (n=90, 3.4%, 95% CI 2.7–4.1), retained nonviable pregnancy (n=2, 0.1%, 95% CI
0–0.2) and incomplete abortion (n=43, 1.6%, 95% CI 1.1–2.1). Of those with continuing pregnancies, 81
underwent a uterine aspiration and 9 opted to continue the pregnancy. Thirty-ﬁve (1.3%, 95% CI 0.9–1.7)
women had signiﬁcant adverse events; 16 (0.6%, 95% CI 0.3–0.9) underwent an in-hospital aspiration. Pelvic in-
fection (n=4, 0.2%) and transfusion (n=1, 0.03%) occurred rarely.
Conclusion:Medical abortion from64 to 70 dayswithmifepristone and vaginalmisoprostol is effectivewith a low
rate of serious adverse events.
Implications:Medical abortion between 64 and 70 days of gestation may be offered on an outpatient basis using
mifepristone and vaginal misoprostol. Service provision without an in-person follow-up is feasible. Not all
women with a continuing pregnancy after medical abortion treatment opt to have an aspiration procedure.
© 2019 Elsevier Inc. All rights reserved.Keywords:
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Continuing pregnancy1. Introduction
Medical abortion with mifepristone 200 mg orally and misoprostol
800 mcg vaginally [1–3] or buccally [4] is highly effective through
63days of gestation [1–4]. Inmany countries,women use thesemedica-
tions on an outpatient basis and expel the pregnancy at home. A home-
based model of medical abortion is as safe, effective and acceptable toNational Abortion Federation
nterest related to medical abor-
regnancy Advisory Service. Dr.
third-party telephone consults
).
rics and Gynecology, Palo Altowomen as in-clinic care [5]. In countries like Britain and the United
States, where this model predominates, abortions in the ﬁrst 9 weeks
of gestation are now induced more frequently with mifepristone and
misoprostol than by surgical evacuation [6–8].
Recent research shows that the upper gestational age limit for out-
patient regimens using mifepristone and buccal [9,10] misoprostol
may be extended to 70 days of gestation without a clinically signiﬁcant
reduction in effectiveness compared to 57–63 days of gestation [9–11].
Similar efﬁcacy is reported in a small number of cases with sublingual
misoprostol [12]. Few data are available to evaluate outcomes with mi-
fepristone and a single dose of misoprostol vaginally beyond 63 days of
gestation. One prospective cohort study of women treated as inpatients
reported a complete abortion rate of 94.5% in 253 cases treated at 63–
83 days of gestation, [13] a rate similar to the 92.5% rate reported with
buccal misoprostol at 64–70 days of gestation [11].
In 2015, British Pregnancy Advisory Service (BPAS), the largest non-
proﬁt provider of abortion services in the United Kingdom, extended
Table 1
Descriptive characteristics of women undergoing medical abortion at 64–
70 days of gestation at BPAS from 1 May 2015 to 31 October 2016
(N=2673)
Characteristic n (%) or
median (range)
Age (years) 25 (13–49)
Gravidity 2 (1–16)
Parity 1 (0–8)
Prior abortion 903 (33.8%)
Prior cesarean delivery 283 (10.6%)
Race
White 2159 (80.8%)
Black 209 (7.8%)
Asian 215 (8.0%)
Other 90 (3.4%)
Gestational age (days) 67 (64–70)
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to 70 days of gestation using the regimen recommended in national
guidance: mifepristone 200mg orally followed in 24–48 h bymisopros-
tol 800mcg vaginally [14]. Prior to this date, BPAS only offered this care
with admission to a treatment unit. Because only one BPAS unit in the
country offered in-clinic medical abortion care, this pathway created a
signiﬁcant burden for women who needed to travel a long distance to
reach the clinic and often resulted in an overnight stay. This report de-
scribes an evaluation of the effectiveness and safety of the outpatient
regimen during the ﬁrst 18 months of the service.
2. Material and methods
2.1. Medical abortion protocol
Women desiring an abortion had an initial consultation, which in-
cluded gestational age dating by vaginal or abdominal ultrasound
using dating criteria of Hadlock et al. [15]. Those eligible for and
requesting a medical abortion swallowed mifepristone 200 mg in the
clinic. Due to legal restrictions on the home use of misoprostol in Britain
during the evaluation period [16], women returned to the clinic in 24–
48 h for misoprostol 800mcg vaginal insertion either self-administered
or by a nurse, depending on the woman's preference. Women then
went home to complete the abortion. Women chose between a fol-
low-up visit with a clinical assessment and ultrasound scan 1–2 weeks
after mifepristone administration or a self-assessment using a low-sen-
sitivity pregnancy test (1000 IU) and a symptom checklist 2 weeks after
treatment [17]. Clinicians instructed those choosing self-assessment to
contact the clinic if they had one or more triggers on the checklist or a
positive or indeterminate urine pregnancy test; clinic staff scheduled
these women for an in-person clinical assessment that included an ul-
trasound scan. Clinicians offered surgical evacuation towomenwith on-
going pregnancies. For those diagnosed with an incomplete abortion
(persistent heavy bleeding or crampingwith heterogenous intrauterine
contents) or a retained nonviable gestational sac, clinicians offered the
choice of an additional dose of misoprostol, expectant management or
a surgical evacuation. Surgical evacuation may also have been per-
formed for other indications such as brisk bleeding, hemodynamic in-
stability, infected retained tissue or patient request.
2.2. Data abstraction and analysis
We identiﬁed all women scheduled for a medical abortion from 64–
70 days of gestation from May 1, 2015, to 31 October 31, 2016, using
BPAS' electronic Booking and Invoicing System. BPAS has 63 clinics in
England and Wales of which 55 clinics provided medical abortion
from 64 to 70 days of gestation. We performed a chart review and ex-
cluded cases with no locatable records and when women did not pro-
ceed with medical abortion or did not use misoprostol following
mifepristone if abortion had not occurred. We also excluded women
who scheduled in-person follow-up and did not return or who
contacted the clinic due to a self-assessment trigger but did not attend
a scheduled appointment. A research nurse and research assistant ex-
tracted demographic characteristics, treatment and follow-up details,
and outcomes (including reasons for failure and any complications)
onto an anonymized data collection form and then entered the ﬁndings
into a secure database for analysis. Themedical record did not include a
distinct variable documenting intended follow-upmethod, so this exact
information could not be ascertained. We cross-referenced BPAS' elec-
tronic adverse events database to capture any other incidents reported
by clinical staff or received from external providers (e.g., general practi-
tioners) and reviewed any discharge summaries from hospitals or doc-
tors received to accurately record any diagnoses or interventions. We
deﬁned signiﬁcant adverse events as emergency department presenta-
tion or inpatient hospitalization (further categorized bywhether the cli-
nician performed an aspiration), transfusion and pelvic infection.We deﬁned the primary outcome, treatment success, as complete
abortion without surgical intervention and without continuing preg-
nancy. Secondary outcomes included indications for surgical evacuation
and signiﬁcant adverse events.
We also evaluated the total number ofwomenwho receivedmedical
and surgical abortion services at 64–70 days gestation for the 18months
prior to and during this analysis. We used these outcomes to determine
the proportion of women in each time period who obtained medical
abortion.
Weused Fisher's Exact Testing for statistical evaluationswith a pb.05
considered signiﬁcant. The funding source had no involvement is study
design, data analysis and interpretation, or preparation of the manu-
script. The BPAS Research and Ethics Committee and the Institutional
Review Board at the University of California, Davis, approved and
exempted the study from full human subjects review.
3. Results
Of the 2743 scheduled medical abortion cases at 64–70 days of ges-
tation during the 18-month study period, we could not locate 40 (1.5%)
medical records and excluded 30 (1.1%) women, including 21who used
mifepristone alone but did not abort, 6 who did not proceed with a
medical abortion and 3 who did not follow up to assess outcome
when clinically indicated. We describe the demographic characteristics
of the ﬁnal sample of 2673 women in Table 1.
Treatment outcomes are summarized in Table 2. Of the 2538
(94.9%, 94.1–95.8)with a complete abortion, 9 (0.4%, 95% CI 0.1–0.6) ex-
pelled the pregnancy with mifepristone treatment only. Overall, 287
(10.7%) women had an in-person follow-up evaluation as intended,
due to a need for further assessment or due to a complication. Of the
90 cases of continuing pregnancy, 81 (90%, 95% CI 83.8–96.2) chose a
uterine aspiration. Overall, 126 (4.7%) women had a uterine aspiration
for continuing pregnancy, incomplete abortion or retained sac.
Thirty-ﬁve (1.3%, 95% CI 0.9–1.7) women experienced 37 signiﬁcant
adverse events; no deaths occurred. The majority of the adverse events
included presentation to an emergency department or inpatient admis-
sion (n=32, 1.2%, 95% CI 0.8–1.6).Womenwhovisited a hospital related
to the medical abortion did so most commonly for a bleeding-related
complaint (n=28, 1.0%, 95% CI 0.7–1.4). However, only 12 (0.4%, 95%
CI 0.2–0.7) required an aspiration during that visit; one (0.04%, 95% CI
0–0.1) of these women also received a blood transfusion. Infections in-
cluded three (0.1%, 95% CI 0–0.2) women diagnosed as outpatients with
pelvic infection and one woman admitted to the hospital with sepsis.
This latter patient had anongoingpregnancy that she opted to continue;
she presented approximately 8 months later in sepsis having delivered
amacerated fetus and subsequently required a hysterectomy due to the
infection.
In the 18 months prior to the outpatient service initiation, 6 of 5479
(0.1%) eligible women at 64–70 days of gestation opted for medical
Table 2
Medical abortion outcomes in cases at 64–70 days of gestation at BPAS from 1May 2015
to 31 October 2016 (N=2673)
Outcome n (%, 95% CI)
Success 2538 (94.9%, 94.1%–95.8%)
Failure: overall 135 (5.1%, 4.2%–5.9%)
Continuing pregnancy 90 (3.4%, 2.7%–4.1%)
Incomplete abortion 43 (1.6%, 1.1%–2.1%)
Retained nonviable sac 2 (0.1%, 0%–0.2%)
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6762 (40.6%) chose medical abortion (pb.001).
4. Discussion
This analysis in more than 2600 women who received mifepristone
200 mg orally followed 24–48 h later by misoprostol 800 mcg vaginally
for abortion from 64 to 70 days of gestation provides a large dataset
within this gestational age range and demonstrates that the regimen
is effective with a low incidence of signiﬁcant adverse events. These
ﬁndings conﬁrm those of an earlier, smaller study of women managed
with this regimen at 63–83 days of gestation [13] and are comparable
to other reports of medical abortion at 64–70 days of gestation with
buccal and sublingual misoprostol (Table 3). These outcome rates are
similar to those reported in the U.S. Food and Drug Administration
label for mifepristone in the United States based on two studies as
shown in Table 3 [11]. Of note, the continuing pregnancy rate appears
to be about the same whether vaginal or buccal misoprostol is used.
However, the overall treatment success rate is slightly higher with vag-
inal compared to buccal misoprostol (Table 3). Given the lower success
rate in this gestational age range compared to earlier gestations [1–4],
future research could address additional misoprostol dosing or alterna-
tive regimens.
Providers may be concerned about a higher incidence of other ad-
verse events with outpatient medical abortion as gestational age ad-
vances, in particular, the risk of hemorrhage and need for acute
intervention or blood transfusion. In our study, 1.2% of women pre-
sented to hospital for assessment related to the medical abortion. Al-
though the main complaint in about half of cases was heavy bleeding,
reassuringly, only 6 (0.2%) women needed emergency aspiration and
only 1 (0.04%) needed a transfusion. This transfusion rate is lower
than the 0.5% reported in a study using misoprostol buccally at 57–
70 days gestation and in linewith the overall rates for women of all ges-
tational ages through 70 days in the U.S. mifepristone label [11]. A U.S.
study representing 54,911 medical and surgical abortions in CaliforniaTable 3
Outcomes of medical abortion at 64–70 days in the literature and including this report a
First author Year
published
Study design Mifepristone
dose
Misoprostol
dose
Number of
women evalua
Hsia (current
study)
– Retrospective 200 mg 800 mcg
vaginally
2673
Gouk [13] 1999 Prospective 200 mg 800 mcg
vaginally
127
Bracken [12] 2014 Prospective 200 mg 400 mcg
sublingual
321
Winikoff [10]b 2012 Prospective 200 mg 800 mcg
buccally
304
Smith [18]b 2015 Prospective 200 mg 800 mcg
buccally
147
Total vaginal
misoprostol
2800
Total buccal
misoprostol
451
a Only includes studies reporting outcomes with at least 50 women at 64–70 days.
b Study comprising the data used for mifepristone U.S. Food and Drug Administration label
c p value=.04 comparing successful abortion rates of total vaginal and total buccal misopro
d p value=.78 comparing continuing pregnancy rates of total vaginal and total buccal misopduring 2009–10 reported a similar emergency department visit rate of
0.9% [19]. The medical abortions in the California study only included
women through 9 weeks of gestation for whom the signiﬁcant adverse
event ratewas 0.31%, lower than our rate of 1.3%. This differencemay be
related to gestational age of our cohort or differential use of hospital ser-
vices in the U.K. where access is free.
The relatively large sample size of this study compared to other eval-
uations of single-dose outpatient medical abortion regimens at 64–
70 days of gestation is a strength.Weaknesses include the retrospective
nature of the review and our inability to know the exact proportion of
women who planned self-assessment vs. in-person follow-up. A prior
study in BPAS clinics demonstrated that most (87.2%) women assigned
to have ofﬁce follow-up reported a priori a preference for remote fol-
low-up [20], a rate similar to the 89.3% non-in-person follow-up rate
in our population. An additional weakness, the use of self-assessment
for follow-up by most women in the analysis, meant that identiﬁcation
of treatment failures and other complications required the woman or
another care provider such as a general practitioner informed BPAS of
the issue or thewoman returned to BPAS for assessment.We attempted
tominimizemissing any complications by reviewing the case notes and
cross-referencing with BPAS' complications and booking databases.
However, some womenmay have received treatment of a complication
elsewhere without informing BPAS. In cases in which a woman in-
formed BPAS of a complication, details may have been relayed inaccu-
rately in some cases. Management of adverse events, such as the
threshold for blood transfusion or choice of intravenous or oral antibi-
otics, can also differ between clinicians and across institutions. Addi-
tionally, despite staff training staff in the reporting and coding of
incidents, there can be errors and omissions in the reporting process.
As would be expected, women infrequently chose medical abortion
at 64–70 days of gestation prior to the availability of an outpatient ser-
vice. Based on the initial signiﬁcant increase in uptake, implementation
of an outpatient regimen has successfully enhanced access to medical
abortion for women at these gestational ages. In 2017 in Scotland [21]
and 2018 for England [22] and Wales [23], the respective Secretaries
of State approved home use ofmisoprostol followingofﬁcemifepristone
administration. Associated guidelines, and in the case of England the ap-
proval wording itself, limit home use of misoprostol to 69 days of gesta-
tion. These decisions will reduce the burden of multiple clinic visits and
may further increase medical abortion uptake, including beyond
63 days of gestation. Our data support the safety and efﬁcacy of this reg-
imen through 70 days of gestation; these governments should consider
amending guidance and approval wordings accordingly.
Our ﬁndings provide further support for the outpatient administra-
tion of mifepristone and misoprostol for medical abortion at 64–ted
Successful
abortion
p value compared to
current study
Continuing
pregnancy rate
p value compared to
current study
2538
(94.9%)
– 90 (3.4%) –
120 (94.5%) .83 7 (5.5%) .21
295 (91.9%) .03 7 (2.2%) .32
282 (92.8%) .11 9 (3.0%) .87
135 (91.8%) .12 5 (3.4%) 1.0
2658
(94.9%)c
97
(3.5%)d
417
(92.5%)c
14
(3.1%)d
[7].
stol groups (Fisher’s Exact Test).
rostol groups (Fisher’s Exact Test).
181J.K. Hsia et al. / Contraception 100 (2019) 178–18170 days of gestation and add to the existing evidence that themisopros-
tol may be administered by the vaginal route.
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